Circassia Achieves Successful Phase II Clinical Results With Toleromune(R) Anti-Allergy Technology Circassia Ltd, a specialty biopharmaceutical company focused on controlling immune system responses, announced positive results from a phase II clinical study of its anti-allergy technology, ToleroMune(R), in the field of cat allergy. The trial showed that ToleroMune treatment can substantially reduce allergic reactions to the allergen that causes most cat allergies, and importantly was well tolerated by all patients.
Source: www.medicalnewstoday.comMind Comments On Research Into Rates Of Escape From Secure Hospitals, UK In response to research by the BBC into the numbers of mental
health patients who escape from low-medium secure hospitals, Mind's Chief Executive Paul Farmer said: "The vast majority of mental
health patients in low to medium secure mental
health hospitals have committed no offence at all. The link between violence and mental
health problems is grossly exaggerated. Any tragedies that do occur are terrible, but it's important to recognise that such cases are rare.
Source: www.medicalnewstoday.comChina Sky One Medical, Inc. Announces 26 New Drugs In Clinical Trials China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Amex: CSY), a leading fully integrated pharmaceutical company producing over-the-counter
drugs in the People's Republic of China ("PRC"), announced that it successfully developed 26 new
drugs that are currently in clinical trials. Heilongjiang Tianlong Pharmaceutical, Inc.
Source: www.medicalnewstoday.com
# posted by Network @ 4:00 AM
